Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2016

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

Résumé

There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.

Domaines

Cancer
Fichier principal
Vignette du fichier
PDFEqu14.pdf (6.63 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

inserm-01319327 , version 1 (20-05-2016)

Identifiants

  • HAL Id : inserm-01319327 , version 1
  • PUBMED : 27172791

Citer

Julien Fleurence, Denis Cochonneau, Sophie Fougeray, Lisa Oliver, Fanny Geraldo, et al.. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget, 2016. ⟨inserm-01319327⟩
261 Consultations
172 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More